Effect of Helminth Infection on HIV-1 Vaccines

蠕虫感染对 HIV-1 疫苗的影响

基本信息

  • 批准号:
    8213688
  • 负责人:
  • 金额:
    $ 36.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-02-15 至 2014-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The worldwide AIDS epidemic is most devastating in developing countries where more than 40 million people are infected. The development of an HIV-1 vaccine for populations in southern Africa and other developing countries is the highest priority. The majority of inhabitants in developing countries are also infected with parasitic helminthes which drive Th2-biasing and immune suppression. Helminth infection suppresses immune responses to Th1-type vaccines, and the expansion of viral antigen specific CD4+ and CD8+ T cell responses. Th1-type and cytotoxic CD8+ T cell responses are the goal of the majority of HIV-1 candidate vaccines in development or in clinical trials. Thus, how helminth infection will impact not only the induction of robust T cell responses to candidate HIV-1 vaccines but also the durability of these T cell responses is an important question. DNA/Adenoviral vector vaccines have shown great success in driving systemic and or mucosal vaccine-specific antibody, CD4+ and CD8+ T cell responses to HIV-1, as well as other pathogens. Thus the first goal of this application is to determine if DNA/Adenoviral vector HIV-1 vaccines will induce strong vaccine specific T cell responses following elimination of helminth parasites. To mimic the scenario in developing countries, we next ask if these vaccine specific T cell responses are maintained in mice that become re-infected with helminth parasites. In this same regard we will determine how re-infection during the vaccination regimen impacts the induction of vaccine specific T cell responses. We will also determine whether F4/80+,Gr1+ suppressor macrophages and/or CD4+,CD25+ T regulatory cells play prominent roles in suppression of HIV-1 vaccine specific T cell responses in helminth mice. Lastly, because the majority of HIV-1 transmission in developing countries is via mucosal sites, we ask if helminth infection differentially impacts systemic vs mucosal HIV-1 vaccine specific T cell responses in helminth infected mice. The specific aims of this proposal are: 1) Will eradication of schistosome infection and restoration of normal immune bias allow for successful vaccination with HIV-1 candidate vaccines in mice? 2) Will established immune responses to HIV-1 vaccines remain durable or be altered by subsequent infection with immunomodulatory helminthes? 3) Does helminth infection differentially impact systemic vs mucosal HIV-1 vaccine specific T cell responses?
描述(由申请人提供):全球艾滋病流行在发展中国家最具破坏性,超过4000万人感染。为南部非洲和其他发展中国家的人口研制艾滋病毒-1疫苗是最高优先事项。发展中国家的大多数居民也感染了寄生蠕虫,这些蠕虫驱动Th 2偏置和免疫抑制。蠕虫感染抑制对Th 1型疫苗的免疫应答,以及病毒抗原特异性CD 4+和CD 8 + T细胞应答的扩增。Th 1型和细胞毒性CD 8 + T细胞应答是大多数HIV-1候选疫苗在开发或临床试验中的目标。因此,蠕虫感染如何不仅影响对候选HIV-1疫苗的稳健T细胞应答的诱导,而且影响这些T细胞应答的持久性是一个重要的问题。DNA/腺病毒载体疫苗在驱动针对HIV-1以及其他病原体的全身和/或粘膜疫苗特异性抗体、CD 4+和CD 8 + T细胞应答方面已经显示出巨大的成功。因此,本申请的第一个目标是确定DNA/腺病毒载体HIV-1疫苗在消除蠕虫寄生虫后是否会诱导强烈的疫苗特异性T细胞应答。为了模拟发展中国家的情况,我们接下来询问这些疫苗特异性T细胞应答是否在再次感染蠕虫寄生虫的小鼠中维持。在这方面,我们将确定疫苗接种方案期间的再感染如何影响疫苗特异性T细胞应答的诱导。我们还将确定F4/80+、Gr 1+抑制性巨噬细胞和/或CD 4+、CD 25 + T调节细胞是否在蠕虫小鼠中抑制HIV-1疫苗特异性T细胞应答中发挥重要作用。最后,因为大多数HIV-1在发展中国家的传播是通过粘膜网站,我们问蠕虫感染是否差异影响系统与粘膜HIV-1疫苗特异性T细胞反应蠕虫感染的小鼠。该提案的具体目标是:1)根除HIV-1感染和恢复正常免疫偏倚是否允许在小鼠中成功接种HIV-1候选疫苗?2)对HIV-1疫苗建立的免疫应答是否会保持持久,或因随后感染免疫调节蠕虫而改变?3)寄生虫感染对系统性与粘膜HIV-1疫苗特异性T细胞应答的影响是否不同?

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10.
  • DOI:
    10.1016/j.vaccine.2009.11.019
  • 发表时间:
    2010-02-03
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Da'dara, Akram A.;Harn, Donald A.
  • 通讯作者:
    Harn, Donald A.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donald A Harn其他文献

Donald A Harn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donald A Harn', 18)}}的其他基金

The Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7877043
  • 财政年份:
    2009
  • 资助金额:
    $ 36.39万
  • 项目类别:
The Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7418170
  • 财政年份:
    2009
  • 资助金额:
    $ 36.39万
  • 项目类别:
Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7923569
  • 财政年份:
    2008
  • 资助金额:
    $ 36.39万
  • 项目类别:
Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7760839
  • 财政年份:
    2008
  • 资助金额:
    $ 36.39万
  • 项目类别:
Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7494355
  • 财政年份:
    2008
  • 资助金额:
    $ 36.39万
  • 项目类别:
Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    7565900
  • 财政年份:
    2008
  • 资助金额:
    $ 36.39万
  • 项目类别:
Effect of Helminth Infection on HIV-1 Vaccines
蠕虫感染对 HIV-1 疫苗的影响
  • 批准号:
    8013546
  • 财政年份:
    2008
  • 资助金额:
    $ 36.39万
  • 项目类别:
Prophylactic Vaccines for Schistosomiasis
血吸虫病预防疫苗
  • 批准号:
    7923601
  • 财政年份:
    2007
  • 资助金额:
    $ 36.39万
  • 项目类别:
Prophylactic Vaccines for Schistosomiasis
血吸虫病预防疫苗
  • 批准号:
    7782810
  • 财政年份:
    2007
  • 资助金额:
    $ 36.39万
  • 项目类别:
Prophylactic Vaccines for Schistosomiasis
血吸虫病预防疫苗
  • 批准号:
    7591665
  • 财政年份:
    2007
  • 资助金额:
    $ 36.39万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 36.39万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 36.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了